Introduction. Cancer-related cognitive impairment (CRCI) can have detrimental effects on quality of life, even among patients with non-central nervous system (CNS) cancers. Several studies have explored different markers associated with CRCI to understand its pathobiology. It is proposed that the underlying mechanisms of CRCI are related to a cascade of physiologic adaptive events in response to cancer and/or its treatment. Hence, peripheral blood would be the most logical source to observe and identify these physiologic events. This paper outlines the protocol for a scoping review which will summarize the extant literature regarding blood-based biomarkers of CRCI among non-CNS cancer patients.
INTRODUCTION
Improved survival after cancer treatment has led to greater impetus to minimize the longterm adverse effects of the disease and its treatment. Cancer-related cognitive impairment (CRCI) is now widely regarded as a prevalent and clinically significant issue among adult patients with non-central nervous system tumors, particularly after systemic treatment with chemotherapy 1, 2 . CRCI is typically characterized by problems in memory, attention, processing speed and executive functioning 3, 4 . The potential consequences of CRCI on survivors' quality of life are significant, including emotional well-being, return to work, and ability to engage effectively in self-care 5, 6 in the months to years after treatment.
Numerous reviews of clinical studies of non-CNS cancer patients indicate wide variation
in the severity, trajectory and duration of CRCI that can be expected after cancer treatment [7] [8] [9] [10] [11] [12] [13] .
Estimates of prevalence have also varied widely, ranging from 17-75% of patients depending on how CRCI is measured 12, [14] [15] [16] . CRCI has demonstrated associations with a range of factors, such as treatment severity, overall functional status and affective symptoms, but the findings are largely mixed 12, 16, 17 . Ultimately, the identification of patients most likely to experience persistent cognitive outcomes remains unclear and effective interventions for routine use have yet to be established [18] [19] [20] . To address these gaps, a greater understanding of the biological mechanisms underlying CRCI is needed.
Several candidate mechanisms of CRCI have been proposed, including inflammation and cytokine dysregulation, chemotherapy-induced epigenetic changes, blood-brain barrier disruption, hormone deficiencies, oxidative DNA damage and shortened telomere length, and genetic susceptibility [21] [22] [23] [24] [25] [26] . However, the heterogeneity and design limitations within the emerging body of evidence has led to recommendations for harmonizing study methodologies and moving towards multi-site, longitudinal research 3, 27 . Such approaches would support the demonstration of robust relationships between measurable biological process and cognitive outcomes.
In this context, the use of peripheral blood as a source of biomarkers in CRCI research is appealing. Biomarkers, or biological markers, have been broadly defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention" (p. 89) 28 . Peripheral blood offers a rich source of circulating proteins, metabolites, cells and genomic markers that may reflect processes underlying CRCI. For example, cytokines produced in the periphery reach the brain through several pathways, including directly through the blood-brain barrier, to stimulate microglia and other immune cells to secrete pro-inflammatory cytokines in the brain, which at elevated levels can produce negative effects to learning, memory, and neuronal plasticity 29 . The identification of candidate biomarkers for CRCI in peripheral blood would hasten the collection of serial samples on a large scale. Aligned with the movement towards personalized medicine, the determination of sensitive and specific blood-based biomarkers could lead to their use in stratifying risk for poor cognitive outcomes and treatment decision making.
This paper describes the protocol of a scoping review currently being conducted to summarize the extant literature regarding blood-based biomarkers of cognitive impairment among non-CNS cancer patients. Recent papers have explored the evidence specific to selected mechanisms of CRCI [21] [22] [23] 30 , but to our knowledge, a mapping of the evidence on the potential array of blood-based biomarkers for CRCI has not been conducted. The study will follow the methodology of Arkey and O'Malley 31 and refined by Levac 32 , which outlines a six-stage process for conducting scoping reviews. The scoping review is guided by the following research question:
• What blood-based biomarkers have been associated with cancer-related cognitive impairment in non-CNS cancer patients?
For the purposes of this review, blood-based biomarkers are operationalized as molecular indicators detected in blood, blood products, plasma or serum. We define CRCI as difficulties in thinking processes, including but not limited to memory, attention, concentration, processing speed, and executive functioning, among patients with a cancer diagnosis 3, 33, 34 . The database search will be supplemented by a review of the table of contents for relevant journals from 2006-present (see Table 1 ), review of bibliography of included studies ("snowballing"), and forward citation tracking of included studies in Scopus and Web of Science. Consultation with content experts will also be conducted to determine if known relevant articles are missing from the list of included studies. Studies selected for the scoping review will be included if they: (1) are clinical studies of patients with a cancer diagnosis; (2) enrolled adults (≥ 18 years of age); (3) include a measurement of blood-based biomarkers; (4) include a subjective or objective assessment of cognitive functioning; (5) report on the association between the biomarker and cognitive functioning; and (6) are written in English. Studies will be excluded that focus on cancers of the central nervous system or pediatric cancer, due to likely differences in pathology of cognitive 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 impairment in these populations. Case reports, editorials, letters, literature reviews, meeting abstracts, and dissertations will be excluded.
Study selection will occur through two phases. In phase I, titles and abstracts of citations will be screened for relevance in duplicate, by two independent reviewers, based on the research question and inclusion/exclusion criteria. Citations determined as relevant will be retrieved in full-text and proceed to phase II screening. In phase II, the inclusion and exclusion criteria will be applied to each of the full-text articles by two independent reviewers. Included studies will form the basis of the scoping review; otherwise, reasons for study exclusion after full-text review will be documented. In both phases of study selection, interrater reliability between reviewers on determinations of study inclusion will be assessed by calculating a Cohen's κ statistic 35 , and strong agreement (κ ≤ 0.80) 36 will be ensured prior to proceeding. Any disagreements between the two reviewers will be resolved by a third reviewer.
Given the exploratory and iterative nature of scoping studies, reviewer meetings throughout the course of the study selection process will allow for the discussion, clarification, and refinement of inclusion/criteria as needed 31, 32 .
Stage 4: Charting the Data "Charting" the data involves the standardized collection of key items of information from the included studies, which will form the basis of the analysis 31 . A data charting form developed by the research team will be used to ensure that the most appropriate data is collected from each study to answer the research question. The data to be extracted from each study will include: publication year, study location, study aim, study design, sample size, cancer diagnoses, severity of disease (e.g., metastatic, non-metastatic), cancer treatment received, demographic Independent data extraction by two reviewers on a shared 10 articles will be used to assess clarity of the data charting form and consistency across reviewers. Discrepancies will be discussed in collaboration with a third reviewer and revisions made to the data charting form as required. After consistency is determined, each additional included study will have data extracted by a single reviewer. (2) reporting results, and (3) applying meaning to the results. In the first step, data analysis will involve a descriptive numerical summary analysis and a qualitative analysis. The descriptive numerical summary will include a description of included studies, such as number of studies included, types of study designs, sample characteristics, cognitive assessment tools, and will be developed based on a review of the data and discussion of the results with all members of the research team. In the second step, a list of the blood-based biomarkers that have shown associations with cognitive functioning will be reported, with details of the relevant evidence about these relationships. In the third step, the broader meaning of the results will be considered through a narrative overview that will characterize dominant lines of research regarding potential blood-based biomarkers of cognitive functioning, identify opportunities and gaps in the current body of evidence, and the potential implications on clinical practice, policy, and future research.
Stage 6: Consultation
Consultation allows for broader stakeholder involvement in the interpretation of the available literature. While stakeholders representing extensive clinical and research expertise in oncology are engaged as part of the research team, a consultation process will be undertaken to engage feedback from external stakeholders that will inform the final presentation of results.
Specifically, diverse perspectives from relevant practice, policy, and research arenas will be sought, in order to enhance the validity and impact of this review.
ETHICS AND DISSEMINATION PLAN
Overall, the current review will characterize dominant lines of research regarding potential blood-based biomarkers of cognitive functioning, emerging topics and gaps in the current body of evidence, and implications of the design of future work in this area. The results of this review will contribute to the refinement of research efforts to identify blood-based biomarkers that are clinically significant and feasible to collect. The dissemination of this work is facilitated through an integrated knowledge translation approach, which includes the involvement of clinicians and researchers on the research team and an external consultation process. Moreover, the presentation of the results through scholarly publication and presentation will contribute to its uptake.
Ethical approval for this review is not required.
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# Searches
1 ((bio* or serum* or serol*) adj4 (mark* or indicator* or characteristic* or factor*)).tw,hw,fs,sh,kw,ot.
2 (biomark* or bio*-mark*).tw,hw,sh,fs,kw,ot.
3 (bio* adj3 mark*).tw,hw,sh,fs,kw,ot. 4 exp Biomarkers/ or "intercellular signaling peptides and proteins"/ or cytokines/ or Biological Factors/ 5 exp Neoplasms/ 6 (cancer* or neoplas* or tu?mor* or malignan* or carcinoma* or malignocarcinoma* or maligno-carcinmoma* or metast* or adenocarci* or adenom*).ti,ab,sh,fs,kw,ot,hw. 7 brain/ or neural pathways/ 8 (neurocognit* or neuro-cognit* or cognit*).tw,hw,sh,fs,kw,ot. 9 exp Cognition/ or cognitive science/ or cognitive neuroscience/ or exp Mental Processes/ 10 ((neuro-cognit* or cognit* or neurocognit* or neural) adj4 (function* or activit* or process*)).tw,hw,sh,fs,kw,ot. 11 ((thought* or think* or memory or attention or reason* or language* or focus*) adj3 (process* or activit* or function*)).tw,hw,sh,fs,kw,ot.
12 (neural adj3 function*).tw,hw,sh,fs,kw,ot. Hence, peripheral blood would be the most logical source to observe and identify these physiologic events. This paper outlines the protocol for a scoping review being conducted to summarize the extant literature regarding blood-based biomarkers of CRCI among non-CNS cancer patients.
Methods/Analysis. Methods will be informed by the updated guidelines of Arksey and O'Malley. The systematic search for literature will include electronic databases, hand-searching of key journals and reference lists, forward citation tracking, and consultation with content experts. Study selection will be confirmed by duplicate review and calculation of interrater reliability. Data to be charted will include study design, sample size, cancer and treatment characteristics, demographic characteristics, cognitive variable/s and biomarkers assessed, associations between cognitive functioning and biomarkers (including statistics used) and rigor in biomarker sample collection and processing. Results will be presented through: (1) a descriptive numerical summary of studies, including a flow diagram based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, (2) a list of blood-based biomarkers associated with CRCI, and (3) a narrative overview developed through collaboration among the research team and consultation with content experts.
Dissemination. The findings of this review will highlight current directions and gaps in the current body of evidence that may lead to improved rigor in future CRCI investigations. The dissemination of this work will be facilitated through the involvement of clinicians and researchers on the research team, an external consultation process, and the presentation of the results through scholarly publication and presentation.
STRENGTHS AND LIMITATIONS OF THIS STUDY
This review will apply scoping review methodology to map the literature regarding bloodbased biomarkers of cancer-related cognitive impairment Interpretation of the data will involve the collaboration of clinicians, researchers, and content experts The review will be limited to research conducted in adults with non-central nervous system cancers and published in English 
INTRODUCTION
Improved survival after cancer treatment has led to greater impetus to minimize the longterm adverse effects of the disease and its treatment. Cancer-related cognitive impairment (CRCI) is now widely regarded as a prevalent and clinically significant issue among adult patients with non-central nervous system tumors, particularly after systemic treatment with chemotherapy 1,2 . CRCI is typically characterized by problems in memory, attention, processing speed and executive functioning 3, 4 . The potential consequences of CRCI on survivors' quality of life are significant, including challenges with emotional well-being, return to work, and ability to engage effectively in self-care 5, 6 in the months to years after treatment.
Numerous reviews of clinical studies of non-CNS cancer patients indicate wide variation
in the severity, trajectory and duration of CRCI that can be expected after cancer treatment 7-13 .
Estimates of prevalence have also varied widely, ranging from 17-75% of patients depending on how CRCI is measured 12, [14] [15] [16] . CRCI has demonstrated associations with a range of factors, such as treatment severity, overall functional status and affective symptoms, but study findings are largely mixed 12, 16, 17 . Ultimately, the identification of patients most likely to experience persistent negative cognitive outcomes remains unclear and effective interventions for routine
use have yet to be established [18] [19] [20] . To address these gaps, a greater understanding of the biological mechanisms underlying CRCI is needed.
Several candidate mechanisms of CRCI have been proposed, including inflammation and cytokine dysregulation, chemotherapy-induced epigenetic changes, blood-brain barrier disruption, hormone deficiencies, oxidative DNA damage and shortened telomere length, and genetic susceptibility [21] [22] [23] [24] [25] [26] . However, the heterogeneity and design limitations within the emerging body of evidence has led to recommendations for harmonizing study methodologies Bringing together the current evidence related to CRCI biomarkers in peripheral blood will suggest priority biomarkers for future investigation in this area, thereby facilitating consistency in research approaches and advancement towards large prospective studies. In addition, aligned with the movement towards personalized medicine, the determination of sensitive and specific blood-based biomarkers could potentially prove useful in stratifying risk for poor cognitive outcomes and guiding treatment decision making in clinical practice.
The purpose of this paper is to report our protocol for a scoping review that will summarize the extant literature regarding blood-based biomarkers of cognitive impairment among non-CNS cancer patients. A scoping review methodology was chosen as it facilitates a characterization of the range and extent of existing evidence available on a given topic, particularly when a body of literature is emerging and expected to be heterogeneous in . While detailed evidence reviews related to select hypothesized biological mechanisms of CRCI have been previously published [21] [22] [23] 32 , we describe in this paper our approach to map the evidence on the potential array of blood-based biomarkers for CRCI more broadly. Such work will inform priority research areas and opportunities for moving towards the identification of blood-based biomarkers that are clinically significant and feasible to collect The study will follow the methodology of Arksey and O'Malley 31 and refined by Levac 33 , which outlines a six-stage process for conducting scoping reviews.
METHODS

Stage 1: Identifying the Research Question
The scoping review is guided by the following research question:
For the purposes of this review, blood-based biomarkers are operationalized as molecular indicators detected in blood, blood products, plasma or serum. We define CRCI as difficulties in thinking processes, including but not limited to memory, attention, concentration, processing speed, and executive functioning, among patients with a cancer diagnosis 3, 34, 35 .
Stage 2: Identifying relevant studies The database search will be supplemented by: 1) hand searches of the table of contents for the past 10 years of key journals known to publish studies related to CRCI (see Table 1 ); 2) review of reference lists of included studies ("snowballing"), and; 3) forward citation tracking of included studies in Scopus and Web of Science. Consultation with content experts, including authors of included studies and individuals identified through our collective research networks, will also be conducted to determine if known relevant articles have been missed.
All records retrieved will be downloaded into a bibliographic software (EndNote) where duplicates will be removed and recorded. Finally, citations will be uploaded to Covidence, an Studies selected for the scoping review will be included if they: (1) are clinical studies of patients with a cancer diagnosis; (2) enrolled adults (≥ 18 years of age); (3) include a measurement of blood-based biomarkers; (4) include a subjective or objective assessment of cognitive functioning; (5) report on the association between the biomarker and cognitive functioning; and (6) are written in English. Studies will be excluded that focus on cancers of the central nervous system or pediatric cancer, due to likely differences in pathology of cognitive impairment in these populations. Case reports, editorials, letters, literature reviews, meeting abstracts, and dissertations will be excluded.
Study selection will occur through two phases using the Covidence platform, In phase I, titles and abstracts of citations will be screened for relevance in duplicate, by two independent reviewers, based on the research question and inclusion/exclusion criteria. Citations determined as relevant will be retrieved in full-text and proceed to phase II screening. In phase II, the inclusion and exclusion criteria will be applied to each of the full-text articles by two independent reviewers. Included studies will form the basis of the scoping review; otherwise, reasons for study exclusion after full-text review will be documented. In both phases of study selection, interrater reliability between reviewers on determinations of study inclusion will be assessed by calculating a Cohen's κ statistic 36 , and strong agreement (κ ≤ 0.80) 37 will be ensured prior to proceeding. Any disagreements between the two reviewers will be resolved by a third reviewer.
Given the exploratory and iterative nature of scoping studies, reviewer meetings throughout the course of the study selection process will allow for the discussion, clarification, and refinement of inclusion/criteria as needed 31, 33 .
Stage 4: Charting the Data "Charting" the data involves the standardized collection of key items of information from the included studies, which will form the basis of the analysis 31 . A data charting form developed by the research team will be used to ensure that the most appropriate data is collected from each study to answer the research question. The data to be extracted from each study will include: publication year, study location, study aim, study design, sample size, cancer diagnoses, severity of disease (e.g., metastatic, non-metastatic), cancer treatment received, demographic Independent data extraction by two reviewers (MA, WB) on a shared 10 studies will be used to assess clarity of the data charting form and consistency across reviewers. Discrepancies will be discussed in collaboration with the principal investigator (SJM) and revisions made to the data charting form as required. After consistency between reviewers is established, each additional included study will have data extracted by a single reviewer (MA or WB) Data extraction for each study will be further reviewed by one of the study investigators to ensure accuracy.
Stage 5: Collating, Summarizing and Reporting the Results
This stage will be comprised of three steps, as recommended by Levac 33 : (1) analyzing the data;
(2) reporting results, and (3) applying meaning to the results. In the first step, data analysis will involve a descriptive numerical summary analysis and a qualitative analysis. The descriptive numerical summary will include a description of included studies, such as number of studies included, types of study designs, sample characteristics, cognitive assessment tools, and biomarkers assessed. In addition, a flowchart based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement 39 will be added to present the flow of studies through the scoping review screening process. A qualitative summary of the results will be developed with involvement from all members of the research team, who will work collaboratively to review the data for overarching patterns and themes. In the second step, a list Specifically, diverse perspectives from relevant practice, policy, and research arenas will be sought through presentation of preliminary findings at various academic conferences and meetings, in order to enhance the validity and impact of this review.
ETHICS AND DISSEMINATION PLAN
Overall, the current review will characterize dominant lines of research regarding potential blood-based biomarkers of cognitive functioning, emerging topics and gaps in the current body of evidence, and implications of the design of future work in this area. The results of this review will contribute to the refinement of research efforts to identify blood-based biomarkers that are clinically significant and feasible to collect. The dissemination of this work is facilitated through an integrated knowledge translation approach, which includes the involvement of clinicians and Ethical approval for this review is not required.
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METHODS
Eligibility criteria 8
Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 6-8
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 6-7
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 Data  management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 7 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 8 Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 8-9
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any preplanned data assumptions and simplifications 8-9
Outcomes and prioritization
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